Outcame of Cases With Hemolytic Uremic Syndrome Attending Assiut University Child Hospital
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03690024|
Recruitment Status : Not yet recruiting
First Posted : October 1, 2018
Last Update Posted : October 1, 2018
|Condition or disease|
|Hemolytic Uremic Syndrome of Childhood|
The disease is caused predominantly by Shiga toxin-producing enterohemorrhagic Escherichia coli (STEC) and is one of the most common etiologies of acute kidney injury (AKI) and an important cause of acquired chronic kidney disease in children . The incidence of HUC tends to parallel the seasonal fluctuation of E.coli o175 : H7 infection which peaks between June & September. Nowadays, the incidence increases and is typically observe in infants and children, especially those aged 6 months to 4 years. A complicated disease course is defined as the development of one or more of the following manifestations: neurological dysfunction, severe bowel injury, pancreatitis, hemodynamic instability (symptomatic hypotension, multi-organ failure), cardiac (congestive heart failure, myocarditis, pericarditis, arrhythmia) or pulmonary involvement (pulmonary edema, acute respiratory distress syndrome), hematologic complications (hemorrhage), and death .
Many laboratory and clinical markers upon admission have been associated to severe forms of the disease, including high initial leukocyte and hematocrit levels, major extrarenal complications, dehydration and recently, the blood urea nitrogen (BUN) to serum creatinine (Cr) ratio , [4-6]. Treatment of D+HUS remains supportive; thus, early identification of high-risk patients can optimize their management [1-3].
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||Outcame of Cases With Hemolytic Uremic Syndrome Attending Assiut University Child Hospital|
|Estimated Study Start Date :||October 1, 2018|
|Estimated Primary Completion Date :||October 1, 2019|
|Estimated Study Completion Date :||December 1, 2019|
- Complete remission [ Time Frame: 1 year ]Number of cases that treated and discharged from hospital
- Death [ Time Frame: 1 year ]Number of cases that ended by death
- Residual renal affection [ Time Frame: 1 year ]Number of cases with residual raised renal chemistry
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03690024
|Contact: Fahim Mohamed Fahim, Professor||01002500073 ext firstname.lastname@example.org|
|Contact: Ahlam Badawy Ali Badawy, Ph.D.||01006807866 ext email@example.com|